KR20190049691A - 심부전의 치료 방법 - Google Patents

심부전의 치료 방법 Download PDF

Info

Publication number
KR20190049691A
KR20190049691A KR1020197003599A KR20197003599A KR20190049691A KR 20190049691 A KR20190049691 A KR 20190049691A KR 1020197003599 A KR1020197003599 A KR 1020197003599A KR 20197003599 A KR20197003599 A KR 20197003599A KR 20190049691 A KR20190049691 A KR 20190049691A
Authority
KR
South Korea
Prior art keywords
oxo
pyrimidine
dihydrothieno
alkyl
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197003599A
Other languages
English (en)
Korean (ko)
Inventor
마이클 이. 멘델손
Original Assignee
카듀리온 파마슈티칼스, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카듀리온 파마슈티칼스, 엘엘씨 filed Critical 카듀리온 파마슈티칼스, 엘엘씨
Publication of KR20190049691A publication Critical patent/KR20190049691A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197003599A 2016-07-07 2017-07-07 심부전의 치료 방법 Ceased KR20190049691A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662359695P 2016-07-07 2016-07-07
US62/359,695 2016-07-07
PCT/US2017/041249 WO2018009899A1 (en) 2016-07-07 2017-07-07 Methods for treatment of heart failure

Publications (1)

Publication Number Publication Date
KR20190049691A true KR20190049691A (ko) 2019-05-09

Family

ID=60912319

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197003599A Ceased KR20190049691A (ko) 2016-07-07 2017-07-07 심부전의 치료 방법

Country Status (7)

Country Link
US (2) US10870656B2 (enExample)
EP (1) EP3481399A4 (enExample)
JP (1) JP2019521192A (enExample)
KR (1) KR20190049691A (enExample)
AU (1) AU2017292918B2 (enExample)
CA (1) CA3030021A1 (enExample)
WO (1) WO2018009899A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10822346B2 (en) * 2018-04-17 2020-11-03 Cardurion Pharmaceuticals, Llc Meglumine salts of thienopyrimidines
TWI816026B (zh) * 2019-03-08 2023-09-21 大陸商藥捷安康(南京)科技股份有限公司 磷酸二酯酶抑制劑的用途和藥盒

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
JP5070052B2 (ja) * 2004-08-17 2012-11-07 ザ・ジョンズ・ホプキンス・ユニバーシティ Ｐｄｅ５阻害剤組成物及び心臓疾患を治療する方法
CN101198614B (zh) * 2005-06-14 2011-07-06 Aska制药株式会社 噻吩并嘧啶衍生物
PL2041139T3 (pl) * 2006-04-26 2012-05-31 Hoffmann La Roche Związki farmaceutyczne
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2011152411A1 (ja) * 2010-05-31 2011-12-08 あすか製薬株式会社 チエノピリミジン誘導体の結晶
EA201600318A1 (ru) * 2013-10-07 2016-09-30 Байер Фарма Акциенгезельшафт Циклические тиеноурацилкарбоксамиды и их применение

Also Published As

Publication number Publication date
EP3481399A1 (en) 2019-05-15
AU2017292918B2 (en) 2021-11-11
JP2019521192A (ja) 2019-07-25
US10870656B2 (en) 2020-12-22
EP3481399A4 (en) 2020-04-01
US20190211028A1 (en) 2019-07-11
CA3030021A1 (en) 2018-01-11
WO2018009899A1 (en) 2018-01-11
AU2017292918A1 (en) 2019-02-07
US20210261567A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
US11046699B2 (en) Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
US20140243357A1 (en) Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
CN1871010B (zh) 门静脉高压的预防和/或治疗
JP2021518842A (ja) グルココルチコイド受容体アンタゴニストを含む固体の形態と製剤、およびその使用
CN108024996A (zh) 布鲁顿氏酪氨酸激酶抑制剂组合和其用途
CN110603038A (zh) 雷帕霉素类似物
TW202539669A (zh) 雌激素受體降解劑之給藥方案
KR101401220B1 (ko) 방사선 치료 증강제
WO2016061555A2 (en) Novel small molecule anticancer agents
US9149471B2 (en) Therapeutic agent for osteoporosis
AU2021291437B2 (en) Acalabrutinib maleate dosage forms
CN105418599A (zh) 新盐及医药用途
US20210261567A1 (en) Methods for treatment of heart failure
KR20140022052A (ko) 심근 경색 후 환자에서의 심부전 및 부정맥 치료를 위한 ａ２ｂ 아데노신 수용체 안타고니스트의 용도
WO2019030275A1 (en) COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREFOR FOR USE IN THE TREATMENT OF FIBROTIC DISEASES
CA2566081A1 (en) Use of dipyridamole for treatment of resistance to platelet inhibitors
ES2934846T3 (es) Inhibidores de CDK para tratamiento de PAH
KR20180002822A (ko) 폐 고혈압의 치료 또는 예방을 위한 방법 및 조성물
WO2024167904A1 (en) Dosage regimens of estrogen receptor degraders in combination with an mtor inhibitor
JPWO2006118212A1 (ja) 膵炎の予防および治療剤
Capan et al. Intra-cystic drug concentration of albendazole sulphoxide in patients with Echinococcus granulosus cysts
NZ551637A (en) Antitumor effect fortifier, antitumor agent and method of therapy for cancer
AU2021333580A9 (en) Combination therapies with olig2 inhibitors
JP2018502863A (ja) 白血病の治療のための４−（４−フルオロ−２−メトキシフェニル）−ｎ−｛３−［（ｓ−メチルスルホンイミドイル）メチル］フェニル｝−１，３，５−トリアジン−２−アミンの使用
CN118678960A (zh) 用于治疗癌症的方法和组合物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190207

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200624

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220425

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20221104

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220425

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I